Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

POTASSIUM HOMEOSTASIS DURING ANGIOTENSIN-CONVERTING ENZYME-INHIBITION WITH ENALAPRIL JOURNAL OF CLINICAL PHARMACOLOGY Scandling, J. D., Izzo, J. L., Pabico, R. C., McKenna, B. A., Radke, K. J., Ornt, D. B. 1989; 29 (10): 916-921

Abstract

The effect of angiotensin-converting enzyme (ACE) inhibition on renal and extrarenal potassium (K) regulation was examined. Six healthy men were studied in double-blinded crossover fashion on placebo or enalapril, 80 mg/day. On day 4, the subjects were given an intravenous infusion of KCl and on day 5 an oral dose of 10% NH4Cl. Treatment with enalapril decreased plasma aldosterone and increased plasma renin activity (PRA), epinephrine and norepinephrine, but did not affect serum glucose, plasma insulin or basal plasma K. Maximal increases in plasma K during K infusion or NH4Cl ingestion were similar during enalapril and placebo treatment. With enalapril treatment urinary K excretion was unchanged following K loading but moderately reduced following NH4Cl loading. We conclude that ACE inhibition does not acutely impair K homeostasis in men with normal renal function.

View details for Web of Science ID A1989CA00900011

View details for PubMedID 2556456